Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Only three drugs – Novo Nordisk’s Wegovy and Saxenda, and Eli Lilly’s Zepbound – are actually ... Videos range from testimonials of rapid weight loss to viral parodies, like the “Ozempic ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Zepbound (tirzepatide) is only available on prescription for people with obesity, or those with overweight. Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Some people who may not be able to receive Ozempic include: Zepbound works by activating the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors to mimic hormones that occur in ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Zepbound is a GLP-1 agonist containing tirzepatide, the same active ingredient found in Mounjaro. While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type 2 diabetes.

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...